Purpose of this Study
We are doing this study to see if an experimental drug called RMC-6236 (the study drug) is a safe and effective option for treating colorectal or pancreatic cancer when it is combined with different chemotherapy drugs.
Who Can Participate?
Eligibility
Adults ages 18+ who:<ul>
<li>Are diagnosed with metastatic or unresectable colorectal cancer; OR</li>
<li>Are diagnosed with metastatic pancreatic cancer</li></ul>
For more information about who can join this study, please contact the study team at <a href= "mailto: gi-oncology-cru@dm.duke.edu">gi-oncology-cru@dm.duke.edu</a> or 919-668-1861.
<li>Are diagnosed with metastatic or unresectable colorectal cancer; OR</li>
<li>Are diagnosed with metastatic pancreatic cancer</li></ul>
For more information about who can join this study, please contact the study team at <a href= "mailto: gi-oncology-cru@dm.duke.edu">gi-oncology-cru@dm.duke.edu</a> or 919-668-1861.
What is Involved?
If you choose to join this study, you will:<ul>
<li>Receive the study drug and chemotherapy with or without irinotecan, or with bevacizumab</li>
<li>Have a tumor biopsy done, if necessary</li>
<li>Have blood draws</li>
<li>Have imaging scans (CT or MRI)</li></ul>
<li>Receive the study drug and chemotherapy with or without irinotecan, or with bevacizumab</li>
<li>Have a tumor biopsy done, if necessary</li>
<li>Have blood draws</li>
<li>Have imaging scans (CT or MRI)</li></ul>
Study Details
Full Title
Study of RMC-6236 in Combination with 5-flourouracil-based Regimens in Patients with Unresectable or Metastatic Colorectal Cancer or Metastatic Pancreatic Ductal Adenocarcinoma? Subprotocol A
Principal Investigator
John
Strickler
Protocol Number
PRO00115657
NCT ID
NCT06445062
Phase
I/II
Enrollment Status
Pending Open to Enrollment